Filed with ASX · · 4 pages · English
LTR Pharma Limited has received ethics approval for a clinical study evaluating SPONTAN in patients with pulmonary arterial hypertension, a serious and currently incurable disease. The study aims to assess whether SPONTAN can rapidly reduce pulmonary vascular resistance within a short time frame after administration. Positive results could lead to further clinical development and commercial opportunities in the growing pulmonary arterial hypertension market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
SPONTAN to be Evaluated in Pulmonary Arterial Hypertension Following Ethics Approval 22 October 2026 Highlights ® • Ethics approval received for an investigator-initiated clinical study evaluating SPONTAN in pulmonary ar- terial hypertension (PAH), a serious, progressive and currently incurable...
